Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

Efti plus Keytruda and chemotherapy achieved a 60.8% ORR and 90.2% DCR in advanced NSCLC patients. The combination therapy showed improved ORR across all PD-L1 expression levels compared to historical ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with ...